Gilead Sciences announces positive results from Veklury and obeldesivir trials Gilead Sciences, announced positive results from several COVID-19 clinical and real-world evidence studies presented at ECCMID. A Phase 3 clinical study demonstrated that Veklury (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which […]

Shionogi demonstrates efficacy of cefiderocol against difficult-to-treat Gram-negative bacterial infections At ECCMID 2023, Osaka, Japan-based Shionogi announced key data for cefiderocol, an innovative siderophore cephalosporin, including new real-world evidence demonstrating its efficacy against some of the most difficult-to-treat Gram-negative bacterial infections.

Influential ECCMID 2023 sees numerous scientific presentations The 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) took place in Copenhagen, Denmark, 15-18 April 2023. With around 14,000 professional attendees ECCMID is the largest international meeting of clinical microbiologists and infectious diseases specialists. The event included a comprehensive scientific programme, an industry programme and […]

by Dr Jacqueline Gosink Biomarkers and preanalytics in Alzheimer’s disease Analysis of biomarkers such as amyloid-beta peptides and tau proteins in cerebrospinal fluid (CSF) is nowadays a core criterion in Alzheimer’s disease diagnostics. Test methods such as ELISA and chemiluminescence immunoassay enable robust and reproducible measurement of the analytes in patient CSF samples. Recommendations for […]